High Dose Chemotherapy in Oligo-metastatic Homologous Recombination Deficient Breast Cancer
Status:
Recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
This study investigates the effect of high-dose alkylating chemotherapy compared with
standard chemotherapy as part of a multimodality treatment approach in patients with
oligo-metastatic breast cancer harboring homologous recombination deficiency.